| Title | Lung Cancer: Targets and Therapy |
| Abbreviation | Lung Cancer: Targets Ther. |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Oncology (Q2) |
| h-index | 25 |
| Overall Rank/Ranking | 5334 |
| SCImago Journal Rank (SJR) | 0.863 |
| Impact Score | 3.68 |
| Publisher | Dove Medical Press Ltd. |
| Country | New Zealand |
| ISSN | 11792728 |
| Best Quartile | Q2 |
| Coverage History | 2010-2022 |
Lung Cancer: Targets and Therapy is a journal covering the technologies/fields/categories related to Oncology (Q2). It is published by Dove Medical Press Ltd.. The overall rank of Lung Cancer: Targets and Therapy is 5334. According to SCImago Journal Rank (SJR), this journal is ranked 0.863. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 25. The best quartile for this journal is Q2.
The ISSN of Lung Cancer: Targets and Therapy journal is 11792728. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Lung Cancer: Targets and Therapy is cited by a total of 164 articles during the last 3 years (Preceding 2022).
The Impact IF 2022 of Lung Cancer: Targets and Therapy is 3.68, which is computed in 2023 as per its definition. Lung Cancer: Targets and Therapy IF is decreased by a factor of 0.06 and approximate percentage change is -1.6% when compared to preceding year 2021, which shows a falling trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2022 of Lung Cancer: Targets and Therapy is 3.68. If the same downward trend persists, Impact IF may fall in 2023 as well.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 3.68 |
| 2021 | 3.74 |
| 2020 | 4.30 |
| 2019 | 4.49 |
| 2018 | 3.19 |
| 2017 | 1.15 |
| 2016 | 0.32 |
| 2015 | 0.47 |
| 2014 | 0.72 |
Lung Cancer: Targets and Therapy has an h-index of 25. It means 25 articles of this journal have more than 25 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Lung Cancer: Targets and Therapy is 11792728. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Lung Cancer: Targets and Therapy is 5334. According to SCImago Journal Rank (SJR), this journal is ranked 0.863. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 0.863 |
| 2021 | 1.056 |
| 2020 | 1.433 |
| 2019 | 1.323 |
| 2018 | 0.768 |
| 2017 | 0.275 |
| 2016 | 0.192 |
| 2015 | 0.357 |
| 2014 | 0.204 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 5334 |
| 2021 | 3758 |
| 2020 | 2445 |
| 2019 | 2789 |
| 2018 | 6183 |
| 2017 | 14153 |
| 2016 | 18251 |
| 2015 | 11859 |
| 2014 | 16950 |
Lung Cancer: Targets and Therapy is published by Dove Medical Press Ltd.. It's publishing house is located in New Zealand. Coverage history of this journal is as following: 2010-2022. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Lung Cancer: Targets and Therapy is Lung Cancer: Targets Ther.. This abbreviation ('Lung Cancer: Targets Ther.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Oncology (Q2), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Lung Cancer: Targets and Therapy latest impact IF is 3.68. It's evaluated in the year 2022. The highest and the lowest impact IF or impact score of this journal are 4.49 (2019) and 0.32 (2016), respectively, in the last 9 years. Moreover, its average IS is 2.45 in the previous 9 years.
The Lung Cancer: Targets and Therapy has an SJR (SCImago Journal Rank) of 0.863, according to the latest data. It is computed in the year 2023. In the past 9 years, this journal has recorded a range of SJR, with the highest being 1.433 in 2020 and the lowest being 0.192 in 2016. Furthermore, the average SJR of the Lung Cancer: Targets and Therapy over the previous 9-year period stands at 2.45.
The latest h-index of the Lung Cancer: Targets and Therapy is 25.
The Lung Cancer: Targets and Therapy is published by the Dove Medical Press Ltd., with its country of publication being the New Zealand.
The Lung Cancer: Targets and Therapy is currently ranked 5334 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 9 years, this journal has experienced varying rankings, reaching its highest position of 2445 in 2020 and its lowest position of 18251 in 2016.
The standard ISO4 abbreviation for the Lung Cancer: Targets and Therapy is Lung Cancer: Targets Ther..
Lung Cancer: Targets and Therapy is classified as a journal that the Dove Medical Press Ltd. publishes.
The Lung Cancer: Targets and Therapy encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Lung Cancer: Targets and Therapy is assigned the following International Standard Serial Numbers (ISSN): 11792728.
The best quartile for the Lung Cancer: Targets and Therapy is Q2 (2022).
The Lung Cancer: Targets and Therapy coverage history can be summarized as follows: 2010-2022.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Business: Theory and Practice | journal | 13414 | Vilnius Gediminas Technical University | 21 | 2.47 |
| IEEE/OSA Journal of Display Technology | journal | 12809 | IEEE Computer Society | 68 | 0.00 |
| Archives of Phytopathology and Plant Protection | journal | 14852 | Taylor and Francis Ltd. | 29 | 1.14 |
| Modern Language Journal | journal | 918 | Wiley-Blackwell | 103 | 3.89 |
| Journal of Sociolinguistics | journal | 5409 | Wiley-Blackwell Publishing Ltd | 61 | 1.96 |
| Exploration Geophysics | journal | 16383 | Taylor and Francis Ltd. | 48 | 1.17 |
| Indian Phytopathology | journal | 14222 | Springer Nature | 11 | 1.33 |
| Proceedings of the Royal Society of Queensland | journal | 22998 | Royal Society of Queensland | 12 | 0.48 |
| SPE International Formation Damage Control Symposium Proceedings | conference and proceedings | 21934 | 16 | 0.00 | |
| Consulting engineer Barrington | journal | 24079 | Cahners Pub. Co. | 0 | 0.00 |
| Year | Impact Score (IS) |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 3.68 |
| 2021 | 3.74 |
| 2020 | 4.30 |
| 2019 | 4.49 |
| 2018 | 3.19 |
| 2017 | 1.15 |
| 2016 | 0.32 |
| 2015 | 0.47 |
| 2014 | 0.72 |
